CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 27, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that members of...
Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq Granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 21, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings,...
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 04, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced...
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today...
CAMBRIDGE, MA, USA & COPENHAGEN, Denmark – March 5, 2026 – Hemab Therapeutics, a late stage clinical biotechnology company developing novel prophylactic therapeutics for serious, underserved coagulation disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted...
Consistent and robust efficacy demonstrated across bleed types, locations, and dose cohorts The weekly dosing cohort achieved an estimated 87% reduction in annualized treated bleeding rate (ATBR) Results validate potential as the first prophylactic therapy to address the heavy physical and...
$157M Series C adds leading life science investors including Sofinnova Partners, a large long-only global asset management company, a large global sovereign wealth fund, and Avoro Capital Advisors Financing readies Hemab for registration studies following successful advancement of sutacimig through...
Seasoned global market access and commercialization expert brings demonstrated track record of successful specialty medicine launches to support Hemab's multiple clinical programs in high unmet need diseases COPENHAGEN, Denmark and CAMBRIDGE, Mass., Sept....
Sutacimig Phase 2 interim results demonstrate >50% reduction in treated bleeding events and prophylactic treatment potential in Glanzmann thrombasthenia HMB-002 clinical proof-of-mechanism data in Von Willebrand disease support its potential as a first-in-class prophylactic therapy by elevating VWF...
Sutacimig (formerly HMB-001) continues to demonstrate promising interim safety, PK, and efficacy Phase 2 results in Glanzmann thrombasthenia and is granted its International Non-Proprietary Name designation by WHO HMB-002 shows promise in Von Willebrand disease with initial proof of mechanism...
